Business
Sutro Biopharma Reports Third Quarter 2020 Financial Results and Provides Business Highlights and Developments
- KOL Discussion of STRO-002 Data Event scheduled for December 3rd - Interim Phase 1 data from STRO-001 for patients with NHL will be presented at ASH -
About this update from Sutro Biopharma, Inc.
[{"type":"text","content":"- KOL Discussion of STRO-002 Data Event scheduled for December 3rd\n - Interim Phase 1 data from STRO-001 for patients with NHL will be presented at ASH\n - Milestone payment received from EMD Serono collaboration on MUC1-EGFR bispecific ADC\n - Honored as Best New Drug Developer at the 7th Annual World ADC Awards\n\n\nSOUTH SAN FRANCISCO, Calif., Nov. 5, 2020 /PRNewswire/ -- Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and autoimmune therapeutics, today reported its financial results for the quarter ended September 30, 2020 and its recent business highlights and developments.\n\"The third quarter of 2020 has been an exciting period for Sutro as we are progressing well on the clinical development of our proprietary antibody-drug conjugate (ADC) candidates. In September at the International Gynecologic Cancer Society Annual Meeting (IGCS), we provided interim data from our STRO-002 dose-escalation Phase 1 trial in ovarian patients with improved efficacy outcomes as our data mature with longer follow-up,\" said Bill Newell, Chief Executive Officer of Sutro Biopharma. \"We look forward to providing a further update in December and also to initiate the dose-expansion portion of the trial in a population who are less heavily pretreated. In addition, we will be sharing our updated interim findings from the non-Hodgkin's lymphoma (NHL) cohort of the STRO-001 dose-escalation Phase 1, which has been accepted at the 62nd Annual Meeting of the American Society of Hematology (ASH). Finally, the Sutro team has been diligently working to advance cancer therapeutics and we were honored to receive The World ADC Best New Drug Developer Award for our work in developing clinical programs including STRO-001, STRO-002, and, in partnership with Bristol Meyers Squibb (BMS), CC-99712.\"\nRecent Business Highlights and Developments\nSTRO-002: Continued progress on our program in STRO-002, folate receptor-alpha (FolRα) targeting ADC for development in ovarian cancer\nThe dose-escalation portion of the STRO-002 Phase 1 clinical trial completed enrollment as of August 31, 2020. Interim data on dose-escalation trial in patients with recurrent platinum resistant or refractory ovarian ca...